Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIIB
stocks logo

BIIB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.22B
-9.7%
1.802
-47.62%
2.27B
-6.74%
3.616
+19.75%
2.37B
-10.38%
3.925
-28.25%
Estimates Revision
The market is revising Upward the revenue expectations for Biogen Inc. (BIIB) for FY2025, with the revenue forecasts being adjusted by 1.92% over the past three months. During the same period, the stock price has changed by 19.45%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.68%
In Past 3 Month
Stock Price
Go Up
up Image
+19.45%
In Past 3 Month
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 174.72 USD with a low forecast of 118.00 USD and a high forecast of 224.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 174.72 USD with a low forecast of 118.00 USD and a high forecast of 224.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
11 Hold
0 Sell
Moderate Buy
Current: 161.480
sliders
Low
118.00
Averages
174.72
High
224.00
Current: 161.480
sliders
Low
118.00
Averages
174.72
High
224.00
Stifel
Hold -> Buy
upgrade
$144 -> $202
2025-11-06
Reason
Stifel
Price Target
$144 -> $202
2025-11-06
upgrade
Hold -> Buy
Reason
Stifel upgraded Biogen to Buy from Hold with a price target of $202, up from $144, following the Q3 report. The firm believes the stock's risk/reward is shifting favorably with clinical catalysts ahead. The upgrade is not a call on the base business, as Biogen's Q3 results were mixed and Q4 "will be just okay," the analyst tells investors in a research note. However, Stifel believes Biogen shares can trade higher in the next 12 months due to a "narrative shift" in Alzheimer's. This will be supported by potential success of Eli Lily's TRAILBLAZER-ALZ 3 trial, which could fundamentally change the way doctors and investors think about amyloid beta antibodies, the analyst tells investors in a research note. Biogen offers "unique optionality even if clinical catalysts still have risks," contends the firm.
Bernstein
Bernstein
Market Perform
maintain
$155 -> $157
2025-11-03
Reason
Bernstein
Bernstein
Price Target
$155 -> $157
2025-11-03
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Biogen to $157 from $155 and keeps a Market Perform rating on the shares following quarterly results. The performance of multiple sclerosis Franchise and to a lesser extent Anti-CD20 drove the revenue beat, outpacing consensus by 14% and 10%, respectively, the firm notes. Leqembi's miss took away the shine from this beat, and while this can be partly explained by channel dynamics, the broader competitive environment looks increasingly challenging, Bernstein adds.
Baird
Outperform
to
NULL
downgrade
$255 -> $250
2025-10-31
Reason
Baird
Price Target
$255 -> $250
2025-10-31
downgrade
Outperform
to
NULL
Reason
Baird lowered the firm's price target on Biogen to $250 from $255 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where its beat was driven by MS as its launch products are showing slow growth.
Jefferies
Andrew Tsai
Buy
initiated
$190
2025-09-24
Reason
Jefferies
Andrew Tsai
Price Target
$190
2025-09-24
initiated
Buy
Reason
Jefferies analyst Andrew Tsai initiated coverage of Biogen with a Buy rating and $190 price target. The firm believes investor expectations are low with Biogen's key risks generally understood. The shares can "grind higher" on any positive developments in 2026, including a Leqembi sales acceleration in Alzheimer's, resiliency of the base business and late-stage pipeline success, the analyst tells investors in a research note. Jefferies sees a favorable risk/reward for Biogen at current levels, saying the stock is trading close to "no-pipeline" value.
Piper Sandler
Neutral
maintain
$115 -> $118
2025-08-14
Reason
Piper Sandler
Price Target
$115 -> $118
2025-08-14
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Biogen to $118 from $115 and keeps a Neutral rating on the shares. The firm says that regarding the two amyloid beta-directed therapies on the market, it is becoming clear that competitive dynamics are not at all amounting to a zero-sum game. That's the good news. That said, Piper continues to see a commercial footprint for the category that is quite limited in the context of the sheer size of the Alzheimer's disease space.
Citi
Neutral
maintain
$125 -> $135
2025-08-01
Reason
Citi
Price Target
$125 -> $135
2025-08-01
maintain
Neutral
Reason
Citi raised the firm's price target on Biogen to $135 from $125 and keeps a Neutral rating on the shares. The company reported a Q2 sales beat with a guidance raise, the analyst tells investors in a research note. Citi wants to see an inflection on new launches and more pipeline progress before recommending the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biogen Inc (BIIB.O) is 12.62, compared to its 5-year average forward P/E of 14.05. For a more detailed relative valuation and DCF analysis to assess Biogen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
14.05
Current PE
12.62
Overvalued PE
17.50
Undervalued PE
10.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.72
Undervalued EV/EBITDA
7.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.91
Current PS
161.48
Overvalued PS
19.68
Undervalued PS
-9.86
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BIIB News & Events

Events Timeline

(ET)
2025-11-03
07:38:19
Biogen to Showcase Advances in Rare Kidney Disease During ASN Kidney Week
select
2025-10-30 (ET)
2025-10-30
06:09:23
Biogen revises FY25 EPS forecast down to $14.50-$15.00, previously $15.50-$16.00
select
2025-10-30
06:06:33
Biogen Announces Q3 Earnings Per Share of $4.81, Exceeding Consensus Estimate of $3.88
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-07WSJ
An Unexpected Pair Is Creating a Weight-Loss Medication, Captivating Big Pharma's Attention.

  • Background: Whit Bernard, originally a music enthusiast, researched the role of music in anti-Soviet uprisings during the Perestroika era, publishing his findings in both English and Latvian.

  • Career Transition: After leaving a music nonprofit in Brooklyn, he pursued business education and became a consultant at McKinsey & Co.

  • Current Involvement: Bernard is now engaged in a significant takeover battle for a new weight-loss drug, indicating a shift from his previous career in music to the pharmaceutical industry.

  • Personal Development: His journey reflects a diverse career path, transitioning from music research to business consulting and now to the competitive pharmaceutical market.

[object Object]
Preview
6.0
11-06CNBC
Major Analyst Recommendations for Thursday: Nvidia, Apple, Caterpillar, Qualcomm, Robinhood, Snap, and Others

  • Nvidia and Arm's Market Position: Bernstein highlights Nvidia's strong position in the robotic chip market, while Bank of America sees significant growth potential for Arm in the data center and AI sectors following its recent earnings report.

  • Upgrades Across Various Companies: Multiple firms upgraded companies like Caterpillar, Biogen, and LegalZoom, citing factors such as AI tailwinds, attractive risk/reward profiles, and impressive earnings performance.

  • Downgrades and Cautions: Piper Sandler downgraded e.l.f. Beauty due to disappointing sales growth projections, while RBC downgraded Bumble, noting ongoing challenges in the online dating sector.

  • Emerging Opportunities in Tech and Finance: Morgan Stanley initiated coverage on Galaxy Holdings, recognizing its potential in AI and blockchain, while Goldman Sachs upgraded Hamilton Lane, emphasizing its strong positioning in alternative asset management.

[object Object]
Preview
4.0
11-06CNBC
Stifel Raises Rating on Biotech Stock Following Change in Alzheimer’s Treatment Narrative

  • Stifel's Upgrade: Stifel upgraded Biogen's stock from hold to buy, raising the target price from $144 to $202, indicating a potential upside of nearly 32%.

  • Analyst Insights: Analyst Paul Matteis noted that while Biogen's third-quarter results were mixed, a narrative shift in Alzheimer's treatment and optionality from lupus drugs could serve as catalysts for the stock.

  • Valuation Context: Matteis highlighted that Biogen trades at a discount compared to peers on an EV/sales basis, suggesting attractive investment opportunities despite challenges in its legacy business.

  • Market Performance: Biogen's shares have increased less than 1% this year, underperforming the S&P 500, which has risen by 15.6% during the same period.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biogen Inc (BIIB) stock price today?

The current price of BIIB is 161.48 USD — it has increased 1.2 % in the last trading day.

arrow icon

What is Biogen Inc (BIIB)'s business?

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

arrow icon

What is the price predicton of BIIB Stock?

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 174.72 USD with a low forecast of 118.00 USD and a high forecast of 224.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biogen Inc (BIIB)'s revenue for the last quarter?

Biogen Inc revenue for the last quarter amounts to 2.53B USD, increased 2.79 % YoY.

arrow icon

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

Biogen Inc. EPS for the last quarter amounts to 3.17 USD, increased 19.17 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biogen Inc (BIIB)'s fundamentals?

The market is revising Upward the revenue expectations for Biogen Inc. (BIIB) for FY2025, with the revenue forecasts being adjusted by 1.92% over the past three months. During the same period, the stock price has changed by 19.45%.
arrow icon

How many employees does Biogen Inc (BIIB). have?

Biogen Inc (BIIB) has 7605 emplpoyees as of November 13 2025.

arrow icon

What is Biogen Inc (BIIB) market cap?

Today BIIB has the market capitalization of 23.69B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free